{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:31:57Z","timestamp":1777941117949,"version":"3.51.4"},"reference-count":41,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Technol Cancer Res Treat"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intrahepatic cholangiocarcinoma (ICC) is the second most common primitive liver cancer and is rising in incidence worldwide. Given its low survival and resectability rates, locoregional therapies such as Yttrium-90 transarterial radioembolization (Y-TARE) are increasingly being employed. This retrospective study aim was to confirm and update our previous results about overall survival (OR), safety, and efficacy of Y-TARE in patients with unresectable\/recurrent ICC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>OS was evaluated as primary endpoint while radiological tumor response at 3 months, based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, was considered as secondary endpoint.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Over a total of 49 patients, the overall median survival was 16 months (27-41 months, 95% confidence interval [CI]) from Y-TARE procedure. A significantly longer survival was recorded in naive patients compared to patients previously submitted to any type of liver-directed treatment and radical surgery (18 vs 14 months,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.015 and 28 vs 14 months,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.001, respectively). Target lesion and overall objective response for RECIST 1.1 criteria were 64.6% and 52.1%, respectively. Low rates of postprocedural and late complications were recorded.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In unresectable and recurrent ICC, Y-TARE confirms its safety and its potential in increasing OS, especially in naive patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/15330338231155690","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T03:44:30Z","timestamp":1679024670000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Update of the Bologna Experience in Radioembolization of Intrahepatic cholangiocarcinoma"],"prefix":"10.1177","volume":"22","author":[{"given":"Cristina","family":"Mosconi","sequence":"first","affiliation":[{"name":"Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Maria","family":"Cacioppa","sequence":"additional","affiliation":[{"name":"Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberta","family":"Cappelli","sequence":"additional","affiliation":[{"name":"Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Giulia","family":"Gramenzi","sequence":"additional","affiliation":[{"name":"Division of Semeiotic, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"Vara","sequence":"additional","affiliation":[{"name":"Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Modestino","sequence":"additional","affiliation":[{"name":"Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1311-5670","authenticated-orcid":false,"given":"Matteo","family":"Renzulli","sequence":"additional","affiliation":[{"name":"Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Golfieri","sequence":"additional","affiliation":[{"name":"Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,3,17]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.01.021"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2016.51"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14095"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2020.06.045"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-016-0866-1"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2019.04.002"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112368"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.21037\/cco.2019.12.15"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-020-02471-z"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10235574"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61903-0"},{"key":"e_1_3_3_13_2","article-title":"Extensive use of interventional therapies improves survival in unresectable or recurrent intrahepatic cholangiocarcinoma","volume":"2016","author":"Seidensticker R","unstructured":"Seidensticker R, Seidensticker M, Doegen K, et al. Extensive use of interventional therapies improves survival in unresectable or recurrent intrahepatic cholangiocarcinoma. Gastroenterol Res Pract. 2016;2016:8732521.","journal-title":"Gastroenterol Res Pract"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2020.08.030"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23781"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0022"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.191"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/153303460900800109"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2014.09.007"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215399"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12574"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.267"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-005-0027-y"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13150"},{"key":"e_1_3_3_26_2","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. U.S. Department Of Health And Human Services National Institutes of Health National Cancer Institute. 2017;November 27."},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-018-5393-3"},{"key":"e_1_3_3_29_2","article-title":"Unresectable intrahepatic cholangiocarcinoma: Multiparametric MR imaging to predict patient survival","author":"Pandey A","year":"2018","unstructured":"Pandey A, Pandey P, Aliyari Ghasabeh M et al. Unresectable intrahepatic cholangiocarcinoma: Multiparametric MR imaging to predict patient survival. Radiology. 2018;288(1):109-117.","journal-title":"Radiology"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2020.02.008"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102258"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04427-z"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2019.03.018"},{"issue":"5","key":"e_1_3_3_34_2","first-page":"161","article-title":"Radioembolization for unresectable intrahepatic cholangiocarcinoma: review of safety, response evaluation criteria in solid tumors 1.1 imaging response and survival","volume":"32","author":"Swinburne NC","year":"2017","unstructured":"Swinburne NC, Biederman DM, Besa C, et al. Radioembolization for unresectable intrahepatic cholangiocarcinoma: review of safety, response evaluation criteria in solid tumors 1.1 imaging response and survival. Cancer Biother Radiopharm. 2017;32(5):161\u2010168.","journal-title":"Cancer Biother Radiopharm"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.3702"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-4199-5"},{"key":"e_1_3_3_37_2","doi-asserted-by":"crossref","DOI":"10.1097\/RLU.0000000000000557","article-title":"PET Response criteria for solid tumors predict survival at three months after intra-arterial resin-based 90Yttrium radioembolization therapy for unresectable intrahepatic cholangiocarcinoma","volume":"39","author":"Camacho JC","year":"2014","unstructured":"Camacho JC, Kokabi N, Xing M, et al. PET Response criteria for solid tumors predict survival at three months after intra-arterial resin-based 90Yttrium radioembolization therapy for unresectable intrahepatic cholangiocarcinoma. Clin Nucl Med. 2014;39(11):944-50.","journal-title":"Clin Nucl Med"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-012-2149-1"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2016.05.020"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1247132"},{"key":"e_1_3_3_41_2","article-title":"Selective interarterial radiation therapy (SIRT) in colorectal liver metastases: how do we monitor response?","author":"Hipps D","unstructured":"Hipps D, Ausania F, Manas DM, et al. Selective interarterial radiation therapy (SIRT) in colorectal liver metastases: how do we monitor response? HPB Surg. 2013;2013(570808).","journal-title":"HPB Surg"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-011-0142-x"}],"container-title":["Technology in Cancer Research &amp; Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338231155690","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15330338231155690","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338231155690","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T06:12:22Z","timestamp":1777702342000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15330338231155690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":41,"alternative-id":["10.1177\/15330338231155690"],"URL":"https:\/\/doi.org\/10.1177\/15330338231155690","relation":{},"ISSN":["1533-0346","1533-0338"],"issn-type":[{"value":"1533-0346","type":"print"},{"value":"1533-0338","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"15330338231155690"}}